Print Page  Close Window

Press Release

Foamix Pharmaceuticals to Present at the Cowen & Company 37th Annual Healthcare Conference

REHOVOT, Israel and BRIDGEWATER, New Jersey, Feb. 27, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President, will present a corporate overview at the Cowen & Company 37th Annual Healthcare Conference, taking place March 6-8 at the Boston Marriott Copley Place in Boston, Massachusetts. 

404614LOGO

Foamix Pharmaceuticals Presentation Details

Date:     

Monday, March 6, 2017

Time:         

3:20pm Eastern Time

Location:    

The Boston Marriott Copley Place, Boston, MA

Webcast:    

http://wsw.com/webcast/cowen38/fomx

About Foamix Pharmaceuticals Ltd.

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit www.foamixpharma.com.

Contact:            

US Investor Relations

Ilan Hadar                       

Michael Rice

Foamix Pharmaceuticals Ltd. 

LifeSci Advisors, LLC

+972-8-9316233      

+1-646-597-6979

IR@foamixpharma.com     

mrice@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/foamix-pharmaceuticals-to-present-at-the-cowen--company-37th-annual-healthcare-conference-300413839.html

SOURCE Foamix Pharmaceuticals Ltd.